
Keywords: DA; dopamine; i.c.v; intra-cerebro-ventricular; l-dopa; levodopa; MPTP; 1 méthyl-4-phenyl-1,2,3,6 terahydropyridine; 6-OHDA; 6-hydroxydopamine; PD; Parkinson's disease; SMBS; sodium metabisulfite; SNpc; substantia nigra pars compacta; Parkinson's disease